ACCG-2671 for Obesity

This trial aims to test a new treatment called ACCG-2671, focusing on its safety and behavior in the body. Researchers will explore how the drug works in both healthy individuals and those with obesity, a condition where body weight significantly exceeds healthy levels. The study consists of different parts: some participants will receive varying doses of the drug or a placebo (a harmless pill with no active drug) to observe its effects, while others will have their reaction to the drug tested with and without food. Part 3 of this trial seeks participants living with obesity (BMI of 30 or higher) who are already on a stable injectable GLP-1RA treatment (a common medication for managing obesity and diabetes) without side effects. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Research has shown that ACCG-2671 is likely safe. In earlier studies, participants generally tolerated the treatment well. No serious negative side effects were reported, and no side effects linked to the drug appeared during treatment. This suggests ACCG-2671 could be safe for humans, but further research is needed to confirm this.¹²³⁴⁵

Unlike the standard treatments for obesity, which often include lifestyle changes, medications like orlistat, or GLP-1 receptor agonists such as semaglutide, ACCG-2671 offers a new approach by being administered orally in ascending and escalating doses. Researchers are excited about ACCG-2671 because it's designed to target weight loss through a potentially novel mechanism not yet seen in current medications. Additionally, the trial explores the drug's effectiveness under different conditions, like fasting and fed states, which could provide insights into optimizing its use for better results. This could mean a more tailored and efficient treatment option for individuals struggling with obesity.

Research has shown that ACCG-2671 yields promising results in weight loss. In earlier studies, this treatment caused significant weight loss in obese rats. Specifically, a previous study with people demonstrated that participants lost up to 16.2% of their body weight over 72 weeks, with no slowdown in weight loss. This trial will evaluate ACCG-2671 in various contexts, including escalating doses for participants living with obesity. The treatment targets specific body parts to help control appetite and weight. These early findings suggest it might be an effective option for managing obesity.⁴⁶⁷⁸⁹